


## Data Snapshot

### AFME Securitisation: Q3 2017

- In Q3 2017, EUR 48.1 bn of securitised product was issued in Europe<sup>1</sup>, a decrease of 34% from Q2 2017 (EUR 72.4 bn) and an increase of 3% from Q3 2016 (EUR 46.5 bn)<sup>2</sup>
- Of this, EUR 22.9 bn was placed, representing 48% of the total, compared to EUR 39.6 bn placed in Q2 2017 (representing 55% of 72.4 EUR bn) and EUR 21.5 bn placed in Q3 2016 (representing 46% of 46.5 EUR bn)
- In Q3 2017, Pan European CLOs led placed totals followed by UK RMBS and Dutch RMBS:
  - Pan European CLOs decreased from 14.0 EUR bn in Q2 2017 to 10.4 EUR bn in Q3 2017
  - UK RMBS decreased from 17.3 EUR bn in Q2 2017 to 4.0 EUR bn in Q3 2017
  - Dutch RMBS increased from 2.2 EUR bn in Q2 2017 to 2.6 EUR bn in Q3 2017



Values in EUR bn	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017 YtD
European placed	419.2	105.5	24.7	89.8	88.9	87.0	75.9	78.2	83.2	96.7	79.8
European retained	175.7	713.2	399.3	288.1	287.9	170.9	104.8	138.8	133.5	142.1	79.0
European retention (%)	30%	87%	94%	76%	76%	66%	58%	64%	62%	60%	50%
Total European	594.9	818.7	423.9	378.0	376.8	257.8	180.8	217.0	216.6	238.8	158.8
Total US	2,080.5	979.0	1401.7	1225.7	1052.8	1568.5	1517.4	1144.3	1635.4	1796.7	1454.2

**Sources:** Bloomberg, Citigroup, Dealogic, Deutsche Bank, JP Morgan, Bank of America-Merrill Lynch, RBS, Thomson Reuters, UniCredit, AFME & SIFMA

**Notes:** (1) European volumes include transactions from all countries in the European continent, including Russia, Iceland, Turkey and Kazakhstan. European volumes include CLOs and CDOs denominated in all European currencies. (2) Volumes have been subject to periodical revision according to the available updated information.

**Disclaimer:** The AFME Securitisation Data Report (the "Report") is intended for general information only, and is not intended to be and should not be relied upon as being legal, financial, investment, tax, regulatory, business or other professional advice. Neither AFME nor SIFMA represents or warrants that it is accurate, suitable or complete and neither of AFME nor SIFMA or their respective employees or consultants shall have any liability arising from, or relating to, the use of this Report or its contents. Your receipt of the Report is subject to paragraphs 3, 4, 5, 9, 10, 11 and 13 of the Terms of Use which are applicable to AFME's website (available at <http://www.afme.eu/Legal/Terms-of-Use.aspx>) and, for the purposes of such Terms of Use, the Report shall be considered a "Material" (regardless of whether you have received or accessed it via AFME's website or otherwise).